Factor IX (or Christmas factor) is one of the serine proteases of the coagulation system; it belongs to peptidase family S1. Deficiency of this protein causes hemophilia B.
Scope of the Report:
This report studies the Factor IX Deficiency Treatment market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Factor IX Deficiency Treatment market by product type and applications/end industries.
In this market study, analysts have estimated the prophylaxis segment to dominate the factor IX deficiency treatment market during the forecast period. Factors such a low cost and high efficiency are the key contributors to the dominance of this segment in the global market.
The global hemophilia B drugs market is expected to grow at a moderate pace during the forecast period. The growing incidence of hemophilia B is expected to drive the market growth. Also, the increasing demand for novel recombinant extended half-life products coupled with the emergence of monoclonal antibodies and gene therapy products will propel the growth of this segment in the next few years.
The global Factor IX Deficiency Treatment market is valued at xx million in 2017 and is expected to reach xx million by the end of 2023, growing at a CAGR of xx% between 2017 and 2023.
The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.
North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Factor IX Deficiency Treatment.
Europe also play important roles in global market, with market size of xx million in 2017 and will be xx million in 2023, with a CAGR of xx%.
Market Segment by Companies, this report covers
Pfizer
Shire
Novo Nordisk
Biogen
CSL Behring
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Hemophilia B
Hemophilia B Inhibitors
Market Segment by Applications, can be divided into
Hospitals
Clinics
Other
Frequently Asked Questions
Table Of Content
Table of Contents
1 Factor IX Deficiency Treatment Market Overview
1.1 Product Overview and Scope of Factor IX Deficiency Treatment
1.2 Classification of Factor IX Deficiency Treatment by Types
1.2.1 Global Factor IX Deficiency Treatment Revenue Comparison by Types (2017-2023)
1.2.2 Global Factor IX Deficiency Treatment Revenue Market Share by Types in 2017
1.2.3 Hemophilia B
1.2.4 Hemophilia B Inhibitors
1.3 Global Factor IX Deficiency Treatment Market by Application
1.3.1 Global Factor IX Deficiency Treatment Market Size and Market Share Comparison by Applications (2013-2023)
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Other
1.4 Global Factor IX Deficiency Treatment Market by Regions
1.4.1 Global Factor IX Deficiency Treatment Market Size (Million USD) Comparison by Regions (2013-2023)
1.4.1 North America (USA, Canada and Mexico) Factor IX Deficiency Treatment Status and Prospect (2013-2023)
1.4.2 Europe (Germany, France, UK, Russia and Italy) Factor IX Deficiency Treatment Status and Prospect (2013-2023)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Factor IX Deficiency Treatment Status and Prospect (2013-2023)
1.4.4 South America (Brazil, Argentina, Colombia) Factor IX Deficiency Treatment Status and Prospect (2013-2023)
1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Factor IX Deficiency Treatment Status and Prospect (2013-2023)
1.5 Global Market Size of Factor IX Deficiency Treatment (2013-2023)
2 Manufacturers Profiles
2.1 Pfizer
2.1.1 Business Overview
2.1.2 Factor IX Deficiency Treatment Type and Applications
2.1.2.1 Product A
2.1.2.2 Product B
2.1.3 Pfizer Factor IX Deficiency Treatment Revenue, Gross Margin and Market Share (2016-2017)
2.2 Shire
2.2.1 Business Overview
2.2.2 Factor IX Deficiency Treatment Type and Applications
2.2.2.1 Product A
2.2.2.2 Product B
2.2.3 Shire Factor IX Deficiency Treatment Revenue, Gross Margin and Market Share (2016-2017)
2.3 Novo Nordisk
2.3.1 Business Overview
2.3.2 Factor IX Deficiency Treatment Type and Applications
2.3.2.1 Product A
2.3.2.2 Product B
2.3.3 Novo Nordisk Factor IX Deficiency Treatment Revenue, Gross Margin and Market Share (2016-2017)
2.4 Biogen
2.4.1 Business Overview
2.4.2 Factor IX Deficiency Treatment Type and Applications
2.4.2.1 Product A
2.4.2.2 Product B
2.4.3 Biogen Factor IX Deficiency Treatment Revenue, Gross Margin and Market Share (2016-2017)
2.5 CSL Behring
2.5.1 Business Overview
2.5.2 Factor IX Deficiency Treatment Type and Applications
2.5.2.1 Product A
2.5.2.2 Product B
2.5.3 CSL Behring Factor IX Deficiency Treatment Revenue, Gross Margin and Market Share (2016-2017)
3 Global Factor IX Deficiency Treatment Market Competition, by Players
3.1 Global Factor IX Deficiency Treatment Revenue and Share by Players (2013-2018)
3.2 Market Concentration Rate
3.2.1 Top 5 Factor IX Deficiency Treatment Players Market Share
3.2.2 Top 10 Factor IX Deficiency Treatment Players Market Share
3.3 Market Competition Trend
4 Global Factor IX Deficiency Treatment Market Size by Regions
4.1 Global Factor IX Deficiency Treatment Revenue and Market Share by Regions
4.2 North America Factor IX Deficiency Treatment Revenue and Growth Rate (2013-2018)
4.3 Europe Factor IX Deficiency Treatment Revenue and Growth Rate (2013-2018)
4.4 Asia-Pacific Factor IX Deficiency Treatment Revenue and Growth Rate (2013-2018)
4.5 South America Factor IX Deficiency Treatment Revenue and Growth Rate (2013-2018)
4.6 Middle East and Africa Factor IX Deficiency Treatment Revenue and Growth Rate (2013-2018)
5 North America Factor IX Deficiency Treatment Revenue by Countries
5.1 North America Factor IX Deficiency Treatment Revenue by Countries (2013-2018)
5.2 USA Factor IX Deficiency Treatment Revenue and Growth Rate (2013-2018)
5.3 Canada Factor IX Deficiency Treatment Revenue and Growth Rate (2013-2018)
5.4 Mexico Factor IX Deficiency Treatment Revenue and Growth Rate (2013-2018)
6 Europe Factor IX Deficiency Treatment Revenue by Countries
6.1 Europe Factor IX Deficiency Treatment Revenue by Countries (2013-2018)
6.2 Germany Factor IX Deficiency Treatment Revenue and Growth Rate (2013-2018)
6.3 UK Factor IX Deficiency Treatment Revenue and Growth Rate (2013-2018)
6.4 France Factor IX Deficiency Treatment Revenue and Growth Rate (2013-2018)
6.5 Russia Factor IX Deficiency Treatment Revenue and Growth Rate (2013-2018)
6.6 Italy Factor IX Deficiency Treatment Revenue and Growth Rate (2013-2018)
7 Asia-Pacific Factor IX Deficiency Treatment Revenue by Countries
7.1 Asia-Pacific Factor IX Deficiency Treatment Revenue by Countries (2013-2018)
7.2 China Factor IX Deficiency Treatment Revenue and Growth Rate (2013-2018)
7.3 Japan Factor IX Deficiency Treatment Revenue and Growth Rate (2013-2018)
7.4 Korea Factor IX Deficiency Treatment Revenue and Growth Rate (2013-2018)
7.5 India Factor IX Deficiency Treatment Revenue and Growth Rate (2013-2018)
7.6 Southeast Asia Factor IX Deficiency Treatment Revenue and Growth Rate (2013-2018)
8 South America Factor IX Deficiency Treatment Revenue by Countries
8.1 South America Factor IX Deficiency Treatment Revenue by Countries (2013-2018)
8.2 Brazil Factor IX Deficiency Treatment Revenue and Growth Rate (2013-2018)
8.3 Argentina Factor IX Deficiency Treatment Revenue and Growth Rate (2013-2018)
8.4 Colombia Factor IX Deficiency Treatment Revenue and Growth Rate (2013-2018)
9 Middle East and Africa Revenue Factor IX Deficiency Treatment by Countries
9.1 Middle East and Africa Factor IX Deficiency Treatment Revenue by Countries (2013-2018)
9.2 Saudi Arabia Factor IX Deficiency Treatment Revenue and Growth Rate (2013-2018)
9.3 UAE Factor IX Deficiency Treatment Revenue and Growth Rate (2013-2018)
9.4 Egypt Factor IX Deficiency Treatment Revenue and Growth Rate (2013-2018)
9.5 Nigeria Factor IX Deficiency Treatment Revenue and Growth Rate (2013-2018)
9.6 South Africa Factor IX Deficiency Treatment Revenue and Growth Rate (2013-2018)
10 Global Factor IX Deficiency Treatment Market Segment by Type
10.1 Global Factor IX Deficiency Treatment Revenue and Market Share by Type (2013-2018)
10.2 Global Factor IX Deficiency Treatment Market Forecast by Type (2018-2023)
10.3 Hemophilia B Revenue Growth Rate (2013-2023)
10.4 Hemophilia B Inhibitors Revenue Growth Rate (2013-2023)
11 Global Factor IX Deficiency Treatment Market Segment by Application
11.1 Global Factor IX Deficiency Treatment Revenue Market Share by Application (2013-2018)
11.2 Factor IX Deficiency Treatment Market Forecast by Application (2018-2023)
11.3 Hospitals Revenue Growth (2013-2018)
11.4 Clinics Revenue Growth (2013-2018)
11.5 Other Revenue Growth (2013-2018)
12 Global Factor IX Deficiency Treatment Market Size Forecast (2018-2023)
12.1 Global Factor IX Deficiency Treatment Market Size Forecast (2018-2023)
12.2 Global Factor IX Deficiency Treatment Market Forecast by Regions (2018-2023)
12.3 North America Factor IX Deficiency Treatment Revenue Market Forecast (2018-2023)
12.4 Europe Factor IX Deficiency Treatment Revenue Market Forecast (2018-2023)
12.5 Asia-Pacific Factor IX Deficiency Treatment Revenue Market Forecast (2018-2023)
12.6 South America Factor IX Deficiency Treatment Revenue Market Forecast (2018-2023)
12.7 Middle East and Africa Factor IX Deficiency Treatment Revenue Market Forecast (2018-2023)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
Inquiry For Buying
Factor IX Deficiency Treatment
Request Sample
Factor IX Deficiency Treatment
